Biopreservation Market Sparkling Growth Worldwide Forecasts By 2023

 Market Highlights

Biopreservation plays an important role in healthcare and food industry. It helps to preserve the biological product or material. It uses natural flora of biological material or the products of natural flora to preserve the product. The increasing expenditure on healthcare, a growing number of in vitro fertilization (IVF) centers, increasing awareness about stem cell and its applications are the major factors driving the growth of the global biopreservation market. Additionally, increasing R&D spending and aggressive strategies adopted by the top players, such as mergers and acquisitions are contributing to the growth of the market. For instance, in March 2016, Shanghai Genext Medical Technology Co Ltd announced the acquisition of a US-based Lifeline Scientific for USD 87.8 million this acquisition will help Shanghai Genext Medical Technology to enter into the clinical transplant business.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6407 

The high cost associated with biopreservation instruments and its maintenance, stability issues related to the specimen and lack of skilled personnel for handling the biopreservation process may hamper the growth of the market during the assessment period.

Regional Analysis

The market in the Americas is expected to dominate the global biopreservation market during the forecast period owing to the increasing organ transplantation, increasing healthcare expenditure, and well-established healthcare sector in the region. The European market is expected to be the second-largest due to government funding and support of the healthcare sector and an increasing number of births and with-it continuous increase in demand for umbilical cord preservation. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development, increasing awareness about stem cell and its applications, and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global biopreservation market. The market growth in this region can be attributed to increasing healthcare expenditure and technological advancement in the region.

Segmentation

The global biopreservation market has been segmented on the basis of product, biospecimen, and application.

On the basis of product, the market has been classified as media and equipment. The media subsegment has been further divided into nutrient media, sera, and growth factors and supplements. The equipment segment has been further divided into temperature control systems, accessories, alarms & monitoring systems, incubators, centrifuges, and other equipment. The temperature control systems segment has been further classified as freezers, cryogenic storage systems, thawing equipment, and refrigerators. The biospecimen segment has been divided into human tissue samples, organs, stem cells, and other biospecimens.

The market, by source, has been segmented into regenerative medicine, biobanking, and drug discovery. On basis of regenerative medicine, the market has been divided into cell therapy, gene therapy, and others. Biobanking segment includes human egg, human sperm, and veterinary IVF.

Key Players

Some of the key players in the global biopreservation market are Thermo Fisher Scientific, Inc, VWR International, LLC., CUSTOM BIOGENIC SYSTEMS., BioLifeSolutions Inc., BioCision, Sigma-Aldrich Co., QIAGEN, Lifeline Scientific, Cesca Therapeutics Inc., Core Dynamics, Ltd., Princeton CryoTech, Biomatrica, Inc., Panasonic Biomedical,  Inc., Chart Industries, and ATLANTA BIOLOGICALS

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/biopreservation-market-6407

 

Worldwide Hemangioblastoma Market Witness A Remarkable Growth Projected By 2023

 The global hemangioblastoma market is expected to grow at the rate of 6.1% during the forecast period (2018–2023)

Hemangioblastoma is a type of brain tumor, it is rare and slow growing disease. Uncontrolled growth occurs in the cell linings of blood vessels and it leads to a tumor. The disease-causing factor is unknown, but it is more likely to affect people with von Hippel-Lindau disease history or it can be sporadically. The growing awareness about cancer, increasing number of tumor surgeries, growing demand for advanced therapies and increasing healthcare expenditure are expected to drive the growth of the market. According to National Center for Biotechnology Information, US National Library of Medicine, 80% cases of hemangioblastoma are sporadic, whereas 20 to 25% develop in the context of Von Hippel–Lindau disease and it accounts for 7 to 10% of total brain tumor cases.

The rising cost of tumor treatment and scarcity of experts may hamper the growth of the market during the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6404 

Regional Analysis

The market in the Americas is expected to dominate the global hemangioblastoma market during the forecast period owing to the increasing prevalence of cancer along with the increasing healthcare expenditure, and well-established healthcare sector in the region. According to the American Cancer Society, there will be an estimated 1,735,350 new cancer cases diagnosed and 609,640 cancer deaths in the United States. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, and technological advancement in the region. Germany is the most affected country in the region and it has the highest number of cancer patients. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development, an increasing number of chronic diseases, and favorable government initiatives for healthcare facilities. Asia-Pacific region has a large number of patients and it can provide opportunities for the major players in the market. The market in the Middle East & Africa is likely to account for the smallest share of the global hemangioblastoma market.

Segmentation

The global hemangioblastoma market has been segmented on the basis of tumor site, diagnosis, and treatment.

On the basis of the tumor site, the market has been classified as brain tumor, spinal cord tumor, and retinal tumor. A brain tumor is most common in all the three segments. The diagnosis segment has been classified as CT scan, MRI scan, and angiogram. According to the stage of cancer, experts can ask for multiple diagnostic tests.

The market, by treatment, has been segmented into surgery, chemotherapy, radiotherapy, corticosteroids, and anticonvulsants. Radiotherapy segment has been classified into conformal radiotherapy, intensity modulated radiotherapy (IMRT), stereotactic radiotherapy and radiosurgery. Corticosteroid segment has been further divided into hydrocortisone, dexamethasone, methylprednisolone, and prednisolone. Anticonvulsants segment has been further divided into carbamazepine, lamotrigine, levetiracetam, phenytoin, and sodium valproate.

Key Players

Some of the key players in the global hemangioblastoma market are Eli Lilly and Company, Bedford Laboratories, Astellas US Holding, Inc., DNAtrix, Inc., Advantagene, Inc., Burzynski Research Institute, Inc., Direct Therapeutics, Inc., Cellectar Biosciences, Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/hemangioblastoma-market-6404 

Tenecteplase Drug Market Staggering Double Digit Cagr Till 2023

 Tenecteplase drug is a recombinant enzyme used as a blood thinning agent. It is also called as clot buster, it dissolves the blood clots or clumps so that the blood could flow normally. Tenecteplase drug is mostly used to treat patients having heart-related diseases. Key factors, that favors the growth of this market are an increase in the rate of hypertension patient, increasing number of deep vein thrombosis cases, early aging and sitting for long period of time cause blood clotting. According to the American Heart Association 2017 report every 40 seconds, someone in the U.S has a heart attack. American College of Cardiology 2018 report states the death rate related to high blood pressure (BP) from 2005- 2015, has increased by 10.5%.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6401 

 Further, the report presented statistics like- Coronary heart disease (CHD) (43.8%) is the major cause of deaths attributable to cardiovascular disease (CVD) in the US, followed by stroke (16.8%), high BP (9.4%), heart failure (HF) (9.0%), and other CVDs (17.9%). Further, they projected by 2035, more than 130 million adults in the US population (45.1%) to have some form of CVD. The total costs of CVD are expected to reach USD 1.1 trillion in 2035. Stroke prevalence in adults is 2.7% in the United States. Similarly, as per CDC’s facts and statistics about stroke in the United States report 2017, every 140,000 Americans die every year due to stroke. Thus, the increasing rate of cardiovascular diseases increases the market growth of tenecteplase drug market in this region.

Segmentation

The global tenecteplase drug market is segmented on the basis of application, dosage and end users.

The tenecteplase drug market, by application segmented into myocardial infarction, stroke, deep vein thrombosis. The tenecteplase drug market, by dosage intravenous dosage and intracatheter instillation dosage. Intravenous dosage is sub-segmented into adult and geriatric and intracatheter instillation dosage is sub-segmented into adult, children, and adolescents weighing 30 kg, infants. On the bases of end-user, it is segmented into hospitals and clinics, surgical centers, research centers and other.

Key players

Some of the key players in the global tenecteplase drug market are Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/tenecteplase-drug-market-6401 

Vitamin test Market 2020 - Shares, Revenue, Analysis And Forecasts Till 2023

 Market Highlights

The Vitamin test market is expected to witness tremendous growth owing to the rising prevalence of vitamin deficiency. Other key factors such as the change to sedentary lifestyle, increase in smoking, and increasing consumption of junk food and packaged food, growing geriatric population, rising consumer awareness for vitamin benefits, and technologically advanced laboratories are contributing towards the growth of the market.  However, factors such as, high cost of vitamin test, limitations of the tests like false positives and false negatives and lack of awareness in developing countries are expected to restrict the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6376 

Segmentation

The global Vitamin test market is segmented on the basis of type, technology, and end-user. the vitamin test market, by type, is categorized into vitamin B12 & folic acid test,folic acid (folate) test , carotene (beta carotene) test, vitamin K1 test, vitamin E test, vitamin d 25-dihydroxy (calcitriol) test, vitamin C test, vitamin B12 test, vitamin B6 test, vitamin B5 test, vitamin B3 (niacin) test, vitamin B2 (riboflavin) test, vitamin a (retinol) test, vitamin B1 test. On the basis of Technology, the market is segmented into high-performance liquid chromatography (HPLC), radioimmunoassay, ELISA tests, chemiluminescent immunoassay (CLIA)and liquid chromatography-tandem mass spectrometry. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.

Regional Analysis

The Americas is the largest in the market owing to the increasing prevalence of vitamin deficiency and growing healthcare expenditure. According to the The United States Department of Agriculture in 2014, 50% of Americans are deficient in vitamin A, vitamin C, and magnesium. Such a high incidence of vitamin deficiency drives market growth in this region.

Europe (UK, Belgium, France, and Netherlands) is the second largest vitamin test market during the forecast period. The increasing in awareness for vitamins and vitamin testing drives the market in this region. The European Laboratory of Nutrients (ELN) is an advanced laboratory for testing the nutrient levels in European population. Every year European Laboratory of Nutrients (ELN) organizes an international symposium titled ‘Advanced Clinical Nutrition – Nutrients for Prevention and Cure of Disease’. Thus enhancing vitamin testing market in this region.

Asia-Pacific was projected to be the fastest growing region for the global vitamin test market in 2017. The market is expected to witness growth owing to the rising prevalence of chronic diseases in this region. Also, the presence of technologically advanced countries like China and Japan in this region is expected to influence the market growth in this region.

The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, the rising healthcare services both at the hospital level and in the community are expected to influence the market in a positive way.

Key Players

Some of the key players in the global Vitamin test market are VitaMe Technologies Inc., R-Biopharm AG, Abbott Laboratories, ImmunoDiagnostics Inc., F. Hoffman-La Roche, Siemens AG, Diazyme Laboratories, DiaSorin S.p.A, ORGENTEC Diagnostika GmbH and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/vitamin-test-market-6377 

Healthcare Claims Management Market Up To 2023: Top Companies, Growth Factors Details And Regional Overview By Types & Application

 Market Highlights

Healthcare claims management process comprises of various tasks such as organization, billing, filling, updating, and processing of medical claims related to the diagnosis, treatment, and medication of patients. The healthcare claims management market is driven by factors such as improved focus on quality healthcare services and adoption of cloud-based technology related services. However, integration of claims management solutions, data breaches, loss of confidentiality, and lack of skilled IT professionals in healthcare are some of the factors restraining the growth of this market. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6376 

The global healthcare claims management market is currently dominated by many market players. The key players in the market are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, IBM’s IPD Ultera for Disability Claims provides an integrated “disability claims management workbench”, specific to disability claims processing and without the need for a large-scale replacement project.

Regional Analysis

The market in the Americas is expected to dominate the global healthcare claims management market during the forecast period owing to the of new and innovative treatments & technologies. Also, heavy inflow of investments by various government agencies to improve healthcare IT infrastructure is expected to create opportunities for healthcare claims management solutions providers. According to the National Health Expenditure Accounts (NHEA), U.S. health care spending grew 4.3 percent in 2016, reaching $3.3 trillion or $10,348 per person which accounted for 17.9 percent. Moreover, the increasing investment in the healthcare infrastructure and services in Asia-Pacific offers huge market potential for the players to grow in healthcare claims management solutions market. In addition, proactive government initiatives to spread awareness about the benefits of this technology among the masses have supplemented the market growth. The market in the Middle East & Africa is likely to account for the smallest share of the global healthcare claims management market. The market growth in this region can be attributed to the high cost of healthcare IT solutions.

Segmentation

The global healthcare claims management market has been segmented into component, delivery mode type and end-user.

The market, based on component, has been segmented into software and services.

The market, by delivery mode, has been segmented into on-premise and cloud based.

The market, by type, has been segmented into integrated and standalone.

The market, by end-user has been segmented into healthcare payers and providers.

Key Players

Some of the key players in the global healthcare claims management market are Cerner Corporation, McKesson Corporation, athenahealth, Inc., eClinicalWorks, Optum, Inc., Conifer Health Solutions, nThrive, Inc, Avaya Inc., Oracle Corporation, Infor Inc., Allscripts Healthcare Solutions, Inc., Accenture plc., IBM Corporation, Cognizant Technology Solutions Corporation and Genpact Limited.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/healthcare-claims-management-market-6376 

The Unilateral Vocal Cord Paralysis Market World Leading Key Players Revenue, Share, Analysis And Estimation Till 2023

 Market Highlights

Unilateral vocal cord paralysis is a speech disorder caused by neurological complications, it is the condition where one vocal cord does not move or shows less movement. It can cause a breathy voice, swallowing disability, weak cough and shortness of breath. The increasing cases of speech disorders, rising healthcare expenditure, and technological advancement are the major factors driving the growth of the global unilateral vocal cord paralysis market. Moreover, the growing prevalence of head and neck cancers is likely to boost the growth of the market. According to the American Society of Clinical Oncology (ASCO), It was estimated that 64,690 people will suffer from head and neck cancers and 13,740 deaths will occur due to head and neck cancer in the year 2017.

The increasing surgical treatment rates and scarcity of experts are likely to hinder the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6356 

Regional Analysis

The market in the Americas is expected to dominate the global unilateral vocal cord paralysis market during the forecast period. The presence of a well-established healthcare sector, growing prevalence of voice disorders, and increasing expenditure for the healthcare sector are driving the growth of the market in this region. The European market is expected to be the second-largest due to the support provided by government bodies for the healthcare sector, increasing research and development activities, and improvement in reimbursement policies. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development, increasing healthcare expenditure, and developing healthcare sector and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global unilateral vocal cord paralysis market. The market growth in this region can be attributed to the increasing investment in the healthcare sector in developing countries.

Segmentation

The global unilateral vocal cord paralysis market has been segmented on the basis of treatment, diagnosis, and end-user.

On the basis of treatment, the market has been classified into medical treatment and surgical treatment. The medical treatment segment has been further divided into medication and voice therapy. The voice therapy segment has been further divided into direct voice therapy, voice hygiene treatment, and voice test environment treatment. Direct voice therapy subsegment has been classified into flow phonation and resonant voice and respiratory support technique. Surgical treatment segment has been divided into endoscopic injection and permanent treatment. Permanent treatment segment has been further divided into vocal fold injection and laryngeal framework surgery.

The diagnosis segment has been divided into laryngoscopy and laryngeal electromyography (LEMG) and blood test & scans. Blood test and scans segment has been further classified into X-rays, CT scans, MRI scans.

The market, by end-user, has been segmented into hospitals, clinics, diagnostic centers and others.

Key Players

Some of the key players in the global unilateral vocal cord paralysis market are Stryker Corporation, Hoya Corporation, Teleflex Incorporated, Therapy Solutions Inc., Smiths Group plc, Smart Speech Therapy LLC, Olympus Corporation of the Americas, Medtronic Plc., KARL STORZ SE & Co. KG, RENÚ, Cytophil, Inc., Acclarent, Inc.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/unilateral-vocal-cord-paralysis-market-6356 

Global Next-Generation Sequencing Market Positive Growth And Forecasts By 2023

 Market Highlights

There are various diseases that have their roots in genetics such as cancer, diabetes, Alzheimer’s, arthritis, heart disease, etc. To discover viable treatment for these diseases, researchers are looking to discern how genes work. The next-generation sequencing market has been gaining impetus due to the fact that next-generation sequencing is integral to the field of genomics. The NGS technologies are implemented for several applications, including whole-genome sequencing, de novo assembly sequencing, resequencing, and transcriptome sequencing at the DNA or RNA level. The successful application of next-generation sequencing can lead to predicting genes, protein-coding regions, and pathways.

Illumina, Helicos Biosciences, Thermo Fisher Scientific, Roche, Pacific Bioscience, ABI Life Technologies, and Oxford Nanopore are some of the companies that are implementing different NGS technologies which in turn will augment global next-generation sequencing market which is estimated to reach at a CAGR of 18.05% over the forecast period and USD 20,347.45 Million by 2025.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6354 

Segmentation

The Next Generation Sequencing Market has been classified by Technology, Service and Product, Application, and End-User.

By technology, the next-generation sequencing market has been segmented as whole-genome sequencing, methyl sequencing, whole-exome sequencing, targeted resequencing, CHIP sequencing, RNA sequencing, and de novo sequencing.

By service & product, the next-generation sequencing market has been segmented as consumables, sample preparation, sequencing services, and platforms and services for platforms.

By application, the NGS market has been segmented as genetic screening, drug discovery, diagnostics, agriculture and animal research, and others.

End-users segmentation of the next generation sequencing market includes academic institutes and research centers, pharmaceutical and biotechnology companies, hospitals and clinics, and other end-users.

Regional Analysis

Owing to the rising number of funds being granted for research into genomics and initiatives adopted by the government to rein in cases of genetically occurring diseases and demand to improve the healthcare sector is estimated to augment the growth of the next-generation sequencing market in North America. Increased competition among market players as well as acquisitions and mergers are expected to drive the growth of the market in the region.

The next-generation sequencing market in Europe is expected to hold the second-largest revenue share due to the presence of some of the leading next-generation sequencing technology companies and an educated population inclined on the advancement of next-generation sequencing technology. Though diverse regulations and a fragmented NGS market might restrain the growth of the market in the region, favorable funding scenario and immense support for scientific research would augment the next-generation sequencing market in the region.

The next-generation sequencing market share in Asia-Pacific is projected to witness expansion over the coming years due to growing demand for advanced technology and access to enhanced treatment facilities, better adoption of advanced genomics, an increase in disposable income, and rising investments in diverse treatment options by pharmaceutical companies.

Due to lack of technical knowledge, an underdeveloped healthcare sector, and poor medical facilities the next-generation sequencing market in the Middle East and Africa is expected to garner the smallest share.

Competitive Landscape

Some of the Key Players in the Global Next-Generation Sequencing Market Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., BGI, PerkinElmer, Agilent Technologies, QIAGEN N. V., Macrogen Inc., Oxford Nanopore Technologies, Ltd., and Eurofins Scientific.

Industry News

Recently, Thermo Fisher Scientific launched its Ion Torrent Genexus System, the first fully integrated, next-generation sequencing platform that delivers results economically in a single day. This turnkey solution is designed to enable local hospitals to adopt NGS testing.

According to a study published in Clinical Lung Cancer local hospitals are severely challenged when it comes to providing NGS-based genomic testing at present even though hospitals are where most patients are treated. Due to limitations to NGS adoption, such as product complexity and cost, the vast majority of local molecular laboratories rely on single-gene tests. Some laboratories even have to outsource testing for more comprehensive NGS analysis as single-gene tests fail to provide a complete genomic profile of a tumor. Ion Torrent Genexus System is expected to solve many of the problems faced by hospitals when it comes to gene testing thus increasing growth scope for next-generation sequencing.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354